A5071351007- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- Inflammasome and immune disorders
- SARS-CoV-2 and COVID-19 Research
Universidad Central "Marta Abreu" de las Villas (UCLV)
2020
Center of Molecular Immunology (Cuba)
2020
Victoria School of Management
2020
Abstract Background Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around world has been placed. In Cuba, first case of was reported on March 11. Elderly with multiple comorbidities have most risky population. Although patients present a mild to moderate disease, some developed severe symptoms. One possible mechanisms underlying rapid disease progression is cytokine storm, in which interleukin (IL) -6 seems be major mediator. Itolizumab humanized recombinant...
Abstract Objectives COVID‐19 can lead to a hyperinflammatory state. CD6 is glycoprotein expressed on mature T lymphocytes which crucial regulator of the T‐cell activation. Itolizumab humanised antibody targeting CD6. Nonclinical and clinical data in autoimmune diseases indicate that it lowers multiple cytokines primarily involving Th1/Th17 pathway. The primary objective this study was assess impact itolizumab arresting lung function deterioration patients. Secondary objectives included...
In COVID-19, the inflammatory cytokine-release syndrome is associated with progression of disease. Itolizumab a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The has shown to be safe and efficacious treatment moderate severe psoriasis. Its effect reduction pro-inflammatory cytokines release, including IFN-γ, IL-6 TNF-α. Here, we report outcome three critically ill COVID-19 patients treated itolizumab as part an expanded access protocol. was able reduce...
Abstract Background : Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around world has been placed. In Cuba, first case of was reported on March 11. Elderly with multiple comorbidities have most risky population. Although patients present a mild to moderate disease, some developed severe symptoms. One possible mechanisms underlying rapid disease progression is cytokine storm, in which interleukin (IL) -6 seems be major mediator. Itolizumabis humanized...
Abstract Background : Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around world has been placed. In Cuba, first case of was reported on March 11. Elderly with multiple comorbidities have most risky population. Although patients present a mild to moderate disease, some developed severe symptoms. One possible mechanisms underlying rapid disease progression is cytokine storm, in which interleukin (IL) -6 seems be major mediator. Itolizumab humanized recombinant...
Abstract Background : Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around world has been placed. In Cuba, first case of was reported on March 11. Elderly with multiple comorbidities have most risky population. Although patients present a mild to moderate disease, some developed severe symptoms. One possible mechanisms underlying rapid disease progression is cytokine storm, in which interleukin (IL) -6 seems be major mediator. Itolizumab humanized recombinant...